Profit before tax stood at Rs 487.59 crore in the third quarter of FY25, up 15.49% from Rs 422.16 crore posted in the same period a year ago.
On nine-month basis, the pharma company’s net profit grew 14.57% to Rs 1,047.40 crore on 8.94% rise in revenue from operations to Rs 4,804.56 crore in 9M FY24 over 9M FY23.
Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.